NCT07267000 EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER
| NCT ID | NCT07267000 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Graz |
| Condition | Non-Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2028-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-04-01 with a primary completion date of 2028-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project is about the effect of a 12-week training therapy intervention in patients suffering from non-small cell and small-cell lung cancer. It has widely been accepted that exercise is preventive against certain types of cancer. Individuals following an active lifestyle have a significantly lower risk for several chronic diseases, including cancer, as compared to sedentary ones. However, evidence is still lacking for exercise as part of routine cancer treatment. It has widely been accepted that exercise strongly impacts immune response, and might influence antitumor immune response as well. In this study, patients suffering from lung cancer undergo either a 12-week training program consisting of moderate-intensity continuous exercise (MICE), or a 12-week program with high-intensity interval exercise. Both groups will be compared to a control group receiving standard exercise recommendations. The immunologic response, i.e. cytokine profiles and changes in peripheral blood mononuclear cell (PBMC) characteristics will be the main endpoint. Blood will be taken from the patients at different timepoints, and blood samples will be tested for these immunologic changes. FACS analysis will be used to assess the properties of immune cells and potential changes upon the exercise regimen. Mitochondrial function will be assessed via the Seahorse machine, and mass spectrometry (lipidomics) will be used for the analysis of lipid profile changes.
Eligibility Criteria
Inclusion Criteria: * Patients suffering from non-small cell or small-cell lung cancer of any histologic subtype, irrespective of routine treatment regimen * ECOG 0 or 1 Exclusion Criteria: * Kachexia (BMI\<18.5) * instable bone metastases * orthopedic condition rendering the patient unable to ride a stationary bike * any medical contraindication for exercise and training * a living will against basic or advanced life support
Contact & Investigator
Elisabeth Taucher, Dr. Dr.
PRINCIPAL INVESTIGATOR
Medical University of Graz
Frequently Asked Questions
Who can join the NCT07267000 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Non-Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07267000 currently recruiting?
Yes, NCT07267000 is actively recruiting participants. Contact the research team at lukas.spielbuechler@medunigraz.at for enrollment information.
Where is the NCT07267000 trial being conducted?
This trial is being conducted at Graz, Austria.
Who is sponsoring the NCT07267000 clinical trial?
NCT07267000 is sponsored by Medical University of Graz. The principal investigator is Elisabeth Taucher, Dr. Dr. at Medical University of Graz. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.